Search research articles
Contact Us
Filters
Showing results (21-30 of 36) with videos related to
Page
of 4
Sort By:
The American Journal of Physiology
|
April 11, 1978
Responses of cerebral arteries and arterioles to acute hypotension and hypertension
H A Kontos, E P Wei, R M Navari, et al.
The American Journal of Physiology
|
May 11, 1978
Role of tissue hypoxia in local regulation of cerebral microcirculation
H A Kontos, E P Wei, A J Raper, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 1, 1997
Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis
E A Perez, R M Navari, H G Kaplan, et al.
Metabolism: Clinical and Experimental
|
March 1, 1993
Protein turnover in advanced lung cancer patients
E W Richards, C L Long, K M Nelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 29, 1998
Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy
R J Gralla, R M Navari, P J Hesketh, et al.
Nutrition (Burbank, Los Angeles County, Calif.)
|
July 1, 1992
Glucose metabolism in advanced lung cancer patients
E W Richards, C L Long, K M Nelson, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 1, 1991
Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor
R J Santen, L M Demers, J Lynch, et al.
The American Journal of Physiology
|
April 11, 1981
Mechanism of cerebral arteriolar abnormalities after acute hypertension
H A Kontos, E P Wei, W D Dietrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1995
Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo
R M Navari, S Madajewicz, N Anderson, et al.
Blood Cancer Journal
|
July 26, 2012
Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo
T Kiziltepe, J D Ashley, J F Stefanick, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 36) with videos related to
Sort By:
Page
of 4
The American Journal of Physiology
|
April 11, 1978
Responses of cerebral arteries and arterioles to acute hypotension and hypertension
H A Kontos, E P Wei, R M Navari, et al.
The American Journal of Physiology
|
May 11, 1978
Role of tissue hypoxia in local regulation of cerebral microcirculation
H A Kontos, E P Wei, A J Raper, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 1, 1997
Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis
E A Perez, R M Navari, H G Kaplan, et al.
Metabolism: Clinical and Experimental
|
March 1, 1993
Protein turnover in advanced lung cancer patients
E W Richards, C L Long, K M Nelson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 29, 1998
Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy
R J Gralla, R M Navari, P J Hesketh, et al.
Nutrition (Burbank, Los Angeles County, Calif.)
|
July 1, 1992
Glucose metabolism in advanced lung cancer patients
E W Richards, C L Long, K M Nelson, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 1, 1991
Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor
R J Santen, L M Demers, J Lynch, et al.
The American Journal of Physiology
|
April 11, 1981
Mechanism of cerebral arteriolar abnormalities after acute hypertension
H A Kontos, E P Wei, W D Dietrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1995
Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo
R M Navari, S Madajewicz, N Anderson, et al.
Blood Cancer Journal
|
July 26, 2012
Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo
T Kiziltepe, J D Ashley, J F Stefanick, et al.
Page
of 4